Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial.

ABSTRACT:

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC10864214 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature